These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

157 related articles for article (PubMed ID: 21978679)

  • 1. 4-N-Hydroxy-4-[1-(sulfonyl)piperidin-4-yl]-butyramides as HDAC inhibitors.
    Rossi C; Fincham CI; D'Andrea P; Porcelloni M; Ettorre A; Mauro S; Bigioni M; Binaschi M; Maggi CA; Nardelli F; Parlani M; Fattori D
    Bioorg Med Chem Lett; 2011 Nov; 21(22):6767-9. PubMed ID: 21978679
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Alkyl piperidine and piperazine hydroxamic acids as HDAC inhibitors.
    Rossi C; Porcelloni M; D'Andrea P; Fincham CI; Ettorre A; Mauro S; Squarcia A; Bigioni M; Parlani M; Nardelli F; Binaschi M; Maggi CA; Fattori D
    Bioorg Med Chem Lett; 2011 Apr; 21(8):2305-8. PubMed ID: 21420859
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Set-up of a new series of HDAC inhibitors: the 5,11-dihydrodibenzo[b,e]azepin-6-ones as privileged structures.
    Bigioni M; Ettorre A; Felicetti P; Mauro S; Rossi C; Maggi CA; Marastoni E; Binaschi M; Parlani M; Fattori D
    Bioorg Med Chem Lett; 2012 Sep; 22(17):5360-2. PubMed ID: 22877635
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Design, synthesis and preliminary biological evaluation of N-hydroxy-4-(3-phenylpropanamido)benzamide (HPPB) derivatives as novel histone deacetylase inhibitors.
    Jiao J; Fang H; Wang X; Guan P; Yuan Y; Xu W
    Eur J Med Chem; 2009 Nov; 44(11):4470-6. PubMed ID: 19608304
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Identification of a series of substituted 2-piperazinyl-5-pyrimidylhydroxamic acids as potent histone deacetylase inhibitors.
    Angibaud P; Van Emelen K; Decrane L; van Brandt S; Ten Holte P; Pilatte I; Roux B; Poncelet V; Speybrouck D; Queguiner L; Gaurrand S; Mariën A; Floren W; Janssen L; Verdonck M; van Dun J; van Gompel J; Gilissen R; Mackie C; Du Jardin M; Peeters J; Noppe M; Van Hijfte L; Freyne E; Page M; Janicot M; Arts J
    Bioorg Med Chem Lett; 2010 Jan; 20(1):294-8. PubMed ID: 19906529
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Improved antiproliferative activity of 1,3,4-thiadiazole-containing histone deacetylase (HDAC) inhibitors by introduction of the heteroaromatic surface recognition motif.
    Guan P; Wang L; Hou X; Wan Y; Xu W; Tang W; Fang H
    Bioorg Med Chem; 2014 Nov; 22(21):5766-75. PubMed ID: 25311567
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Discovery of pyridone-based histone deacetylase inhibitors: approaches for metabolic stability.
    Cho M; Choi E; Yang JS; Lee C; Seo JJ; Kim BS; Oh SJ; Kim HM; Lee K; Park SK; Kwon HJ; Han G
    ChemMedChem; 2013 Feb; 8(2):272-9. PubMed ID: 23292995
    [TBL] [Abstract][Full Text] [Related]  

  • 8. New aryldithiolethione derivatives as potent histone deacetylase inhibitors.
    Tazzari V; Cappelletti G; Casagrande M; Perrino E; Renzi L; Del Soldato P; Sparatore A
    Bioorg Med Chem; 2010 Jun; 18(12):4187-94. PubMed ID: 20576572
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Design, synthesis and anticancer activity of piperazine hydroxamates and their histone deacetylase (HDAC) inhibitory activity.
    Chetan B; Bunha M; Jagrat M; Sinha BN; Saiko P; Graser G; Szekeres T; Raman G; Rajendran P; Moorthy D; Basu A; Jayaprakash V
    Bioorg Med Chem Lett; 2010 Jul; 20(13):3906-10. PubMed ID: 20605448
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Amide-based derivatives of β-alanine hydroxamic acid as histone deacetylase inhibitors: attenuation of potency through resonance effects.
    Liao V; Liu T; Codd R
    Bioorg Med Chem Lett; 2012 Oct; 22(19):6200-4. PubMed ID: 22932316
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Synthesis and antitumor activity of novel diaryl ether hydroxamic acids derivatives as potential HDAC inhibitors.
    Zhu Y; Chen X; Wu Z; Zheng Y; Chen Y; Tang W; Lu T
    Arch Pharm Res; 2012 Oct; 35(10):1723-32. PubMed ID: 23139122
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Exploring bis-(indolyl)methane moiety as an alternative and innovative CAP group in the design of histone deacetylase (HDAC) inhibitors.
    Giannini G; Marzi M; Marzo MD; Battistuzzi G; Pezzi R; Brunetti T; Cabri W; Vesci L; Pisano C
    Bioorg Med Chem Lett; 2009 May; 19(10):2840-3. PubMed ID: 19359173
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Design and synthesis of aryl ether and sulfone hydroxamic acids as potent histone deacetylase (HDAC) inhibitors.
    Pabba C; Gregg BT; Kitchen DB; Chen ZJ; Judkins A
    Bioorg Med Chem Lett; 2011 Jan; 21(1):324-8. PubMed ID: 21109435
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Development of novel ferulic acid derivatives as potent histone deacetylase inhibitors.
    Wang F; Lu W; Zhang T; Dong J; Gao H; Li P; Wang S; Zhang J
    Bioorg Med Chem; 2013 Nov; 21(22):6973-80. PubMed ID: 24095016
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Histone deacetylase inhibitors with a primary amide zinc binding group display antitumor activity in xenograft model.
    Attenni B; Ontoria JM; Cruz JC; Rowley M; Schultz-Fademrecht C; Steinkühler C; Jones P
    Bioorg Med Chem Lett; 2009 Jun; 19(11):3081-4. PubMed ID: 19410459
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Synthesis and biological evaluation of 3-(4-substituted-phenyl)-N-hydroxy-2-propenamides, a new class of histone deacetylase inhibitors.
    Kim DK; Lee JY; Kim JS; Ryu JH; Choi JY; Lee JW; Im GJ; Kim TK; Seo JW; Park HJ; Yoo J; Park JH; Kim TY; Bang YJ
    J Med Chem; 2003 Dec; 46(26):5745-51. PubMed ID: 14667227
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Spiro[chromane-2,4'-piperidine]-based histone deacetylase inhibitors with improved in vivo activity.
    Thaler F; Varasi M; Carenzi G; Colombo A; Abate A; Bigogno C; Boggio R; Carrara S; Cataudella T; Dal Zuffo R; Reali V; Vultaggio S; Dondio G; Gagliardi S; Minucci S; Mercurio C
    ChemMedChem; 2012 Apr; 7(4):709-21. PubMed ID: 22354629
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Design and synthesis of novel isoxazole-based HDAC inhibitors.
    Conti P; Tamborini L; Pinto A; Sola L; Ettari R; Mercurio C; De Micheli C
    Eur J Med Chem; 2010 Sep; 45(9):4331-8. PubMed ID: 20637529
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Conformational refinement of hydroxamate-based histone deacetylase inhibitors and exploration of 3-piperidin-3-ylindole analogues of dacinostat (LAQ824).
    Cho YS; Whitehead L; Li J; Chen CH; Jiang L; Vögtle M; Francotte E; Richert P; Wagner T; Traebert M; Lu Q; Cao X; Dumotier B; Fejzo J; Rajan S; Wang P; Yan-Neale Y; Shao W; Atadja P; Shultz M
    J Med Chem; 2010 Apr; 53(7):2952-63. PubMed ID: 20205394
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Benzothiazole-containing hydroxamic acids as histone deacetylase inhibitors and antitumor agents.
    Oanh DT; Hai HV; Park SH; Kim HJ; Han BW; Kim HS; Hong JT; Han SB; Hue VT; Nam NH
    Bioorg Med Chem Lett; 2011 Dec; 21(24):7509-12. PubMed ID: 22036991
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.